Dear Colleague,

Happy New Year!

This month we are pleased to publish our first-ever January issue of Cancer Cytopathology, which heralds our increase from 6 to 12 issues annually! With more issues and more pages, we've also undertaken the development of new content that will bring more variety to every issue and practical and useful information for your practice. In 2013, CytoSource, our news and views section headed up by Dr. Terence Colgan, will alternate with two new solicited sections: Clinician's Corner and Cytopathology Help Desk.

Clinician's Corner, premiering in this issue and edited by Dr. Martha Bishop Pitman, is designed as a brief commentary by a clinician whose practice includes specific management decisions based on cytologic diagnoses. As cytopathologists, we can, and should, be integral partners in patient care; the Corner will highlight these opportunities. Premiering in the March issue, Cytopathology Help Desk, edited by Dr. Gladwyn Leiman, is designed to provide insights and answers to current questions and controversies by experts in our discipline.

Concurrent with our strategic plan to deliver monthly issues of Cancer Cytopathology with added content and new features was the need to restructure the Editorial Board to realize the journal's strategic vision. The Editorial Review Board will continue to be comprised of expert and diligent reviewers whose major responsibility is to ensure that the manuscripts are thoroughly reviewed in a timely fashion. Members of the newly configured Editorial Advisory Board, through their deeper engagement in the vision and mission of the journal, will help us remain dynamic and focused on the future. Cancer Cytopathology will continue to remain preeminent in the field thanks to their contributions and the efforts of all of our reviewers and board members.

I also want to take this opportunity to thank you, our readers and contributors, for helping us to achieve our goal of being the top journal in the field of cytopathology. We measure our success by many different metrics, but of course one of these remains the impact factor, which reached an all-time high this year of 3.333.


As always, we encourage input from our readership, especially as we continue to develop and present new content. Please contact any of our editors with ideas and questions you may want us to address in the future. The Associate Editors and I will work diligently to continue our aspiration not only to publish cutting edge research in cytopathology but to anticipate what you, our readers, need to advance your cytopathology practice.

Sincerely, Celeste N. Powers, MD, PhD Editor-in-Chief, Cancer Cytopathology